Condition: Cancer · Neoplasm · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The objective of this randomized controlled trial (RCT) is to evaluate the effectiveness of the MiLES intervention targeted at employers, on successful return to work (RTW) of employees with cancer, compared to care as usual (CAU). Secundary objectives are: * To evaluate the cost-effectiveness and return-on-investment of the MiLES intervention on successful RTW and quality of life, compared to CAU. * To evaluate the effectiveness of the MiLES intervention on several outcome measures on the level of the employee with cancer (time to RTW, quality of life, quality of working life, received work-related support, and satisfaction with work-related support), and the level of the employer (self-efficacy in providing RTW support, and satisfaction with the RTW process). Participants will be 140 employer-employee with cancer dyads. All dyads will randomly be allocated to the intervention group, of which the employer will get unlimited access to the MiLES intervention, or to the control group in which CAU will be provided. The follow-up of this study will be 12 months. Along with the RCT, a process evaluation using the UK Medical Research Council framework will also be conducted.
This description comes directly from the study's public registry record.
Judith Mollet, MSc · +31205669111 · milesonderzoek@amsterdamumc.nl
Michiel Greidanus, PhD · +31205669111 · m.a.greidanus@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Arbo Unie | Arnhem, Netherlands | Recruiting |
| Arbo Unie | Dordrecht, Netherlands | Recruiting |
| Arbo Unie | Hengelo, Netherlands | Recruiting |
| Re-turn | Utrecht, Netherlands | Recruiting |
| Arbo Unie | Zeeland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06672887